Synaptogenix announces $5.0 million financing

New york , sept. 11, 2024 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx) ("synaptogenix" or the "company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly issued series c convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible into shares of its common stock in a registered public offering (the "registered offering") and a concurrent private placement (the "private placement" and collectively with the registered offering, the "offering") of additional shares of preferred stock and unregistered common stock purchase warrants.
SNPX Ratings Summary
SNPX Quant Ranking